<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282437</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT11</org_study_id>
    <nct_id>NCT01282437</nct_id>
  </id_info>
  <brief_title>Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC</brief_title>
  <acronym>NVALT11</acronym>
  <official_title>Prophylactic Cranial Irradiation (PCI) Versus Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer; A Phase III Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with stage III non-small cell lung cancer, which is radically treated, we will
      investigate whether prophylactic cranial irradiation (PCI) should become standard of care to
      prevent brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this group of patients, brain metastases are one of the major sites of tumor failure.
      Radical therapy of symptomatic brain metastases is seldom possible and only very rarely, long
      term survival can be achieved. PCI has shown to reduce the incidence of brain metastases in
      patients with non-small cell lung cancer to the same extent as in limited disease small-cell
      lung cancer. However, the exact value of PCI in stage III NSCLC patient, treated with
      contemporary chemo-radiation schedule with or without surgery, remains unsettled. Therefore
      this study is launched, in order to investigate whether PCI should become the standard of
      care in patients with stage III NSCLC who are treated with curative intention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients developing symptomatic brain metastasis</measure>
    <time_frame>24 months after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to develop neurological symptoms (confirmed or unconfirmed by imaging)</measure>
    <time_frame>24 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of side effects (CTCAE3.0)</measure>
    <time_frame>24 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months after randomisation</time_frame>
    <description>Measured by QLQ-C30 and EuroQol 5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <condition>Radical Treatment</condition>
  <condition>Stage III Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic Cranial Irradiation</intervention_name>
    <description>18 fractions of 2Gy
12 fractions of 2.5Gy
10 fractions of 3 Gy</description>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UICC stage IIIA or IIIB (without malignant pleural of pericardial effusion) non-small
             cell lung cancer (histology or cytology)

          -  Whole body FDG-PET-scan before start of therapy available: No distant metastases

          -  CT or MRI of the brain before the start of radical therapy available: No brain
             metastases

          -  Platinum-based chemotherapy is mandatory

          -  Radical local therapy: concurrent of sequential chemotherapy (platinum-based) and
             radiotherapy with or without surgery

          -  Radiotherapy dose without surgery at least a biological equivalent of 60Gy

          -  No prior cranial irradiation

          -  Patients must sign a study-specific informed consent at the time of registration

        Exclusion Criteria:

          -  The opposite of the above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NVALT oncology foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Groen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RT Insitute Stedendriehoek</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bernard Verbeeten Institute</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

